WO2014027864A1 - 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균 - Google Patents
노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균 Download PDFInfo
- Publication number
- WO2014027864A1 WO2014027864A1 PCT/KR2013/007410 KR2013007410W WO2014027864A1 WO 2014027864 A1 WO2014027864 A1 WO 2014027864A1 KR 2013007410 W KR2013007410 W KR 2013007410W WO 2014027864 A1 WO2014027864 A1 WO 2014027864A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dementia
- lactobacillus
- strain
- disease
- active ingredient
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the present invention relates to a novel lactic acid bacteria isolated from kimchi, and more specifically, Lactobacillus pentosus var. Plantarum C29 and Lactobacillus ( Lactobacillus pentosus var. Plantarum ) having a preventive and / or therapeutic activity of aging and dementia Lactobacillus curvatus C3.
- the process of aging is influenced by a combination of genetic, environmental, and lifestyle interactions, and is accompanied by a variety of morphological and biochemical changes.
- increased oxidative stress and increased inflammatory response are involved in aging. It is considered to be the main cause.
- Oxidative stress can be caused by increased production of reactive oxygen radicals (ROS) or decreased antioxidant defense mechanisms in the body, resulting in the destruction of biopolymers such as DNA, cell damage, aging, and dementia.
- ROS reactive oxygen radicals
- biopolymers such as DNA, cell damage, aging, and dementia.
- Adler et al. (Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E, Chang HY.Motif module map reveals enforcement of aging by continual NF-kappaB activity.Genes Dev. 2007; 21: 3244-57)
- the association of NF- ⁇ B activating motifs with the units regulating the aging process in tissues and experimental animal tissues demonstrates that the inflammatory process mediated by NF- ⁇ B is closely associated with the aging process.
- aging activates PI3K / AKT, and it is known that phosphorylation of FOXO3 does not inhibit ROS production, resulting in genetic variation.
- Dementia one of the aging diseases, is caused by chronic or progressive disease of the brain, degeneration of brain tissue, degeneration, and aging central nervous system infections (such as neurosyphilis, tuberculous meningitis, viral encephalitis), cerebral infarction, brain injury, and toxic metabolism.
- Disorders, neurological diseases (Parkinson's disease), etc. are known to be the leading cause of dementia.
- Dementia includes Alzheimer's disease, vascular dementia, and other types of dementia. 50-60% of dementia patients aged 65 or older in Korea are Alzheimer's dementia, 15-30% are vascular dementia, and the remaining 10-15% are dementia. It is a combination of these two diseases.
- Beta-amyloid (Aß), a waste product in the brain, is known to be a major cause of Alzheimer's dementia. Many drugs have been tried to treat Alzheimer's dementia. Although acetylcholinesterease inhibitors that act on acetylcholine, one of the important neurotransmitters in the brain, lacked in Alzheimer's dementia patients, it is the only one used as a therapeutic agent, but the drug shows partial improvement in cognitive function. It is known to have no effect on the progression of Alzheimer's disease, and it is required to develop an effective dementia prevention or treatment.
- lactic acid bacteria have been used for a long time, and beneficial effects such as intestinal action, anticancer effect, immune enhancing effect of lactic acid bacteria have been reported. Accordingly, the present inventors have studied to find lactic acid bacteria having a beneficial effect on aging and dementia, and confirmed that the new lactic acid bacteria isolated from kimchi have a prophylactic or therapeutic effect on aging and dementia.
- An object of the present invention is to provide a lactic acid bacterium having a prophylactic or therapeutic effect on aging and dementia.
- an object of the present invention is to provide an antioxidant and anti-aging composition comprising the lactic acid bacteria and a composition for preventing or treating dementia.
- the present invention also provides an antioxidant and anti-aging fermentation composition fermented with the lactic acid bacteria and a fermentation composition for preventing or treating dementia.
- the present invention provides Lactobacillus pentosus var. Plantarum C29 KCCM11291P isolated from kimchi.
- the present invention also provides an antioxidant and anti-aging pharmaceutical composition comprising Lactobacillus pentosus mutant plantarium C29 as an active ingredient.
- the present invention also provides a pharmaceutical composition for preventing or treating dementia, comprising Lactobacillus pentosus mutant plantarium C29 as an active ingredient.
- the present invention provides a dietary supplement with antioxidant and anti-aging effects, comprising Lactobacillus pentosus mutant plantarium C29 as an active ingredient.
- the present invention also provides a dietary supplement for preventing or improving dementia, comprising Lactobacillus pentosus mutant plantarium C29 as an active ingredient.
- the present invention also provides an antioxidant and anti-aging composition
- an antioxidant and anti-aging composition comprising a fermentation composition fermented with Lactobacillus pentosus mutant plantarium C29 as an active ingredient.
- the present invention also provides a composition for the prevention or treatment of dementia, comprising a fermentation composition fermented with Lactobacillus pentosus variety plantarium C29 as an active ingredient.
- the present invention also provides Lactobacillus curvatus C3 KCCM43009 isolated from kimchi.
- the present invention also provides an antioxidant and anti-aging pharmaceutical composition comprising Lactobacillus curbatus C3 as an active ingredient.
- the present invention also provides a pharmaceutical composition for preventing or treating dementia, comprising Lactobacillus curbatus C3 as an active ingredient.
- the present invention also provides a dietary supplement with antioxidant and anti-aging effects, comprising Lactobacillus curbatus C3 as an active ingredient.
- the present invention also provides a dietary supplement for preventing or improving dementia, comprising Lactobacillus curbatus C3 as an active ingredient.
- the present invention also provides an antioxidant and anti-aging composition
- an antioxidant and anti-aging composition comprising a fermentation composition fermented with Lactobacillus curbatus C3 as an active ingredient.
- the present invention also provides a composition for preventing or treating dementia, comprising a fermentation composition fermented with Lactobacillus curbatus C3 as an active ingredient.
- Lactobacillus pentosus mutant plantarium C29 and Lactobacillus curbatus C3 of the present invention are novel microorganisms isolated from Chinese cabbage kimchi.
- the Lactobacillus pentosus mutant plantarium C29 of the present invention is a strain belonging to the Lactobacillus in molecular phylogenetic and biochemical characterization based on the 16s rDNA sequence, and has a high molecular system in both Lactobacillus pentosus and Lactobacillus plantarium. significant flexibility, but identified as a strain showing a relationship between the biochemical characteristics of Lactobacillus was the more similar the pento Saskatchewan named Lactobacillus pento suspension variants Planta volume C29, deposited on July 09, 2012, the international deposit agency, Korea Culture Center of microorganisms Deposited with the number KCCM11291P.
- Lactobacillus curbatus C3 of the present invention was identified as a strain belonging to Lactobacillus curbatus as a strain belonging to Lactobacillus in molecular phylogenetic analysis based on 16s rDNA sequence and was named as Lactobacillus curbatus C3. , It was deposited on July 9, 2012 with the deposit number KCCM43009 to the Korea Microorganism Conservation Center.
- Lactobacillus pentosus strain plantarium C29 (hereinafter also referred to as "C29") and Lactobacillus curbatus C3 (hereinafter referred to as "C3") of the present invention is a passive avoidance test using a mouse model of Alzheimer's disease
- C29 Lactobacillus pentosus strain plantarium C29
- C3 Lactobacillus curbatus C3
- the effect of improving the memory of the mouse was confirmed by administration of the C29 strain or C3 strain in the C29 strain, Y-shaped maze test and aquatic maze test has been shown to improve the memory, proving the prevention and treatment of dementia ( See Example 2).
- dementia refers to a state in which cognitive functions such as memory, language ability, and judgment are continuously and generally deteriorated as the brain function is impaired due to various causes, causing problems in daily life.
- Alzheimer's disease vascular dementia, Lewy body dementia, anterior temporal lobe dementia, Parkinson's disease dementia, Huntington's disease dementia, dementia caused by normal pressure hydrocephalus, dementia caused by head trauma, substance-induced dementia, and the like.
- Lactobacillus pentosus mutant plantarium C29 and Lactobacillus curbatus C3 of the present invention were strains having an excellent effect on the prevention and treatment of dementia and aging.
- Lactobacillus pentosus varieties Planarium C29 of the present invention Morphological and physiological characteristics of the Lactobacillus pentosus varieties Planarium C29 of the present invention, sucrose fermentation assay results, and cellular fatty acid composition are known from Table 1, Table 2 and Table 3, respectively. Planta volume (L.plantarum) ATCC 14917 and L. appear with the characteristics of pento Saskatchewan (L.pentosus) DSM20314.
- None of the three lactic acid bacteria is 2-keto-gluconate, 5-keto-gluconate, erythritol, D-arabinose, L-xylose, ⁇ -methyl-D-xyloxide, L-solvos, inositol , Did not ferment glycogen, xylitol, D-lysose, D-tagatose, D-fucose, L-fucose, L-arabitol.
- Lactobacillus pentosus mutant plantarium C29 strain and Lactobacillus curbatus C3 strain of the present invention can be used for the prevention and treatment of aging and dementia, therefore, the present invention is Lactobacillus pentosus mutant plantarium C29
- An antioxidant and anti-aging pharmaceutical composition comprising the strain or Lactobacillus curbatus C3 strain as an active ingredient, and a pharmaceutical composition for preventing or treating dementia.
- compositions of the invention may be administered orally (eg, by taking or inhaling) or parenterally (eg, by injection, transdermal absorption, rectal administration), and the injection may be, for example, intravenous, subcutaneous. Injection, intramuscular injection or intraperitoneal injection.
- the pharmaceutical compositions according to the invention can be formulated into tablets, capsules, granules, fine subtilae, powders, sublingual tablets, suppositories, ointments, injections, emulsions, suspensions, syrups, sprays and the like depending on the route of administration. Can be converted.
- the pharmaceutical compositions according to the present invention in various forms can be prepared by known techniques using pharmaceutically acceptable carriers commonly used in each formulation.
- Examples of pharmaceutically acceptable carriers include excipients, binders, disintegrating agents, lubricants, preservatives, antioxidants, isotonic agents, buffers, coatings, sweeteners, solubilizers, bases, dispersants, wetting agents , Suspending agents, stabilizers, coloring agents and the like.
- the pharmaceutical composition according to the present invention comprises from about 0.01 to 100% by weight of the Lactobacillus pentosus mutant plantarium C29 strain or Lactobacillus curbatus C3 strain.
- the specific dosage of the pharmaceutical composition of the present invention may vary depending on the type of mammal, including the person being treated, weight, sex, degree of disease, judgment of the doctor, and the like. It will be possible to determine the appropriate dosage according to.
- 0.001 to 500 mg of active ingredient per kg of body weight is administered per day
- 0.01 to 200 mg of active ingredient is administered per kg of body weight per day.
- 100 mg of active ingredient is administered per kg of body weight per day.
- the total daily dose may be administered at one time or divided into several times depending on the extent of the disease, the judgment of the doctor.
- the present invention also provides a health functional food having antioxidant and anti-aging effects and a health functional food for the prevention or improvement of dementia, comprising the C29 strain or C3 strain as an active ingredient.
- dietary supplement of the present invention may be in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, or candy, sweets, gum, ice cream, noodles, bread, beverages. And the like can be added to common foods.
- the health functional food of the present invention may be prepared by appropriately using fillers, extenders, binders, wetting agents, disintegrants, sweeteners, fragrances, preservatives, surfactants, lubricants, excipients and the like in a conventional manner.
- the content of the C29 strain or C3 strain in the manufacture of the health functional food depends on the form of the health functional food, but the concentration of about 0.01 to 100% by weight.
- the present invention also provides a composition having an antioxidant and anti-aging effect and a composition for preventing or improving dementia, comprising a fermentation composition fermented with a C29 strain or a C3 strain as an active ingredient.
- the fermentation composition includes soybean or skim fermentation composition, thaw skin fermentation composition, ginseng fermentation composition, and deodeok fermentation composition.
- the water suspension of soybean or skim soybean powder is used to add 5 to 15 times the water by weight to the dry soybean or skim soybean powder, but is not limited thereto, but is not limited thereto.
- Soy milk may be ground and used in soymilk form as long as it meets the requirements.
- the thawed blood, ginseng, and deodeok may be an extract or extract form, preferably may be used in the form of an extract prepared by hot water extraction, alcohol extraction or mixed extraction method, but is not limited thereto.
- the extract may be ground or powdered to increase the extraction efficiency, and may be performed according to conventional extraction methods known in the art. For example, a water extraction method, an alcohol extraction method, an organic solvent extraction method, a supercritical extraction method, or the like may be used. Preferably, the water extraction method is used, but is not limited thereto.
- the extraction solvent used in the alcohol extraction method may be a lower alcohol having 1 to 6 carbon atoms, such as methanol, ethanol, propanol, isopropanol, butanol and the like.
- Examples of the extraction solvent of the organic solvent extraction method include organic solvents such as acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, hydrochloric acid, acetic acid, formic acid, citric acid, cyclohexane and petroleum ether; Or mixtures thereof.
- the ratio of the extraction solvent added during the extraction is not particularly limited, but the extraction solvent may be used 2 to 20 times (by weight) with respect to the dried weight of thawed skin, ginseng or deodeok. In order to increase the extraction efficiency, it may be repeated two or more times using the extraction solvent 5 times to 15 times (by weight) with respect to thawed skin, ginseng or deodeok.
- the extraction temperature is preferably 50 to 110 °C, more preferably 70 to 100 °C.
- the extraction time depends on the extraction temperature, but is extracted from 1 hour to 48 hours, preferably 2 hours to 8 hours.
- the extraction efficiency can be further increased when stirring with a shaker (shaker) during extraction.
- the extract can be prepared by vacuum distillation or thin film distillation.
- the soybean or skim bean fermentation composition, thawed skin fermentation composition, ginseng fermentation composition, and deodeok fermentation composition fermented by inoculating C29 strain or C3 strain is fermentation in the passive avoidance test using a mouse of Alzheimer's disease animal model The effect of improving memory in mice by administration of the composition was confirmed, demonstrating the prophylactic and therapeutic effect of dementia (see Example 5).
- the inoculation amount of the C29 strain or C3 strain depends on the type of extract used for the fermentation, but is 1 ⁇ 10 8 CFU / ml or more and the fermentation temperature is preferably 20 to 40 ° C.
- Fermentation time is not particularly limited as long as it satisfies the purpose of the present invention, it can be fermented for 10 to 30 hours by inoculating C29 strain or C3 strain.
- Lactobacillus pentosus strain plantarium C29 or Lactobacillus curbatus C3 strain of the present invention has been found to have an excellent prevention and improvement effect against aging and dementia can be usefully used for the prevention or treatment of aging and dementia have. Therefore, the pharmaceutical composition and the dietary supplement comprising the Lactobacillus pentosus mutant plantarium C29 strain or the Lactobacillus curbatus C3 strain of the present invention can be effectively used to prevent or treat aging and dementia, and daily intake. Since the strain present in kimchi is an active ingredient, it can be used without concern about side effects or toxicity.
- Lactobacillus pentosus varieties Planarlium C29 or Lactobacillus Curbatus C3 strain of the present invention can be effectively used as a composition for preventing or treating aging and dementia.
- FIG. 1 shows the 16S rDNA sequence (SEQ ID NO: 1) of C29 lactic acid bacteria.
- FIG. 2 is a phylogenetic tree showing the location of the Lactobacillus pentosus strain plantarium C29.
- Figure 3 is a graph showing the passive avoidance test results.
- 5 is a gel photograph showing the memory improving effect of the C29 strain.
- FIG. 6 is a graph showing the results of the Y-shaped maze test of Example 2.
- FIG. 8 is a gel photograph showing the change in the expression level of aging-related gene phosphate according to the administration of the C29 strain.
- FIG. 9 is a graph showing the results of the Y-shaped maze test of Example 3, where Y is a young mouse, O is an aging mouse, and O / C29 is C29 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU) / mouse) Is an aging mouse administered with O, C3 is an aging mouse administered with C3 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU) / mouse), and O / C24 is a C24 lactic acid bacterium (1 ⁇ 10 9 colony forming unit (CFU). ) / Mouse).
- FIG. 10 is a graph showing the results of the underwater maze test of Example 3, where Y is a young mouse, O is an aging mouse, and O / C29 is a C29 lactic acid bacterium (1 ⁇ 10 9 colony forming unit (CFU) / mouse).
- Aged mouse administered O / C3 is aged mouse administered C3 lactic acid bacteria (1 ⁇ 10 9 colony forming unit (CFU) / mouse)
- FIG. 11 shows the 16S rDNA sequence (SEQ ID NO: 2) of C3 lactic acid bacteria.
- Chinese cabbage was suspended in MRS broth, the supernatant was transplanted into MRS agar medium, and then cultured anaerobicly at 37 ° C. for 24 hours to select grown colonies and analyzed for Gram staining and 16S rDNA. Lactobacillus strains were isolated.
- human feces were suspended in GAM broth (Nissui Pharmaceutical Company, Ltd., Japan), the supernatant was transplanted into BL agar medium (Nissui Pharmaceuticals), and then grown by anaerobic incubation at 37 ° C. for 48 hours. Lactobacillus and Bifidobacterium strains were isolated by gram staining and 16S rDNA analysis.
- the isolated strains are as follows.
- mice All animals used in the experiment were 28-30 g male ICR mice, and the experiment was conducted according to the guidelines for the use and care of experimental animals (NIH publication No. 85-23). Experimental animals were housed 5-6 per cage and left free to eat. The temperature in the kennel was 23 ⁇ 1 °C, the humidity was 60 ⁇ 10%, and the work was always maintained for 12 hours (07:30 ⁇ 19:30).
- the experimental box (50 x 15 x 40cm, electrofiable frid floor) is divided into two compartments by using partitions, and the entrance is automatically closed when entering from one side to the other through a small entrance. Turn on the light on one side of the compartment divided into compartments, look around and enter the dark compartment with no lighting, and the entrance closes automatically, immediately flowing 0.25 mA of current for 1 second through the bottom stainless steel grid. Give a foot shock.
- the passive evasion reaction time is determined to be 300 seconds. It was determined that the greater the time until the animals moved to the dark compartment and the entrance was closed, the better the memory of passive avoidance through learning was maintained.
- C29 lactic acid bacteria which were found to be the most effective, were administered to mice twice daily with 1 ⁇ 10 9 and 1 ⁇ 10 10 CFU (dog). Scopolamine (0.9 mg / kg) was administered 1 hour after the last dose of lactic acid bacteria. As a result, as can be seen in Figure 4, C29 showed an effect depending on the concentration.
- the hippocampus of the brain was isolated and homogenized by adding 100 ⁇ l of RIPA buffer (Gibco) containing a protease inhibitor cocktail. After centrifugation at 4 ° C. and 13000 rpm for 15 minutes, the supernatant was stored at ⁇ 80 ° C., and p-CREB, CREB, BDNF, and ⁇ -actin were measured by immunoblotting.
- the supernatant was taken and subjected to electrophoresis for 1 hour and 30 minutes on SDS 10% (w / v) polyacrylamide gel (sample, 50 ⁇ g).
- the electrophoresis was transferred to nitrocellulose paper at 100 V and 400 mA for 1 hour 10 minutes, the transferred nitrocellulose paper was blocked with 5% skim milk for 30 minutes, washed with PBS-Tween 3 times for 5 minutes, and the primary antibody (Santa Cruz Biotechnology, USA) was reacted 1: 100 overnight. After washing three times for 10 minutes, the secondary antibody (Santa Cruz Biotechnology, USA) was reacted with 1: 1000 for 1 hour and 20 minutes. Thereafter, the mixture was washed three times for 15 minutes, and developed by fluorescence.
- the Y-shaped labyrinth measuring device extends three arms to form the letter Y, each branch 25 cm long, 14 cm high, 5 cm wide and positioned at the same angle. At the end of a passage in the Y-shaped labyrinth, the animal's head is pointed and free to wander about eight minutes. Record the movement of the animal and see it as an arm entry as it enters the passage to the animal's hind paw. The movement of an animal is expressed as alternation, which is defined as one crossing when the animal passes through three passages in a row. Voluntary crossover behavior is expressed as a percentage of the actual crossover and the maximum possible crossover (ie, the total crossover minus two).
- the lactic acid bacterium C29 was administered 1x10 9 and 1x10 10 CFU (dog) once a day for 2 days. Scopolamine (0.9 mg / kg) was administered 1 hour after the last dose of lactic acid bacteria.
- test group administered C29 compared to the test group administered only scopolamine showed a memory-improving effect in a concentration-dependent manner.
- a circular water tank (100 cm diameter, 35 cm high) was filled with powdered milk to a depth of 15 cm to make the platform installed in water at a temperature of 23 ° C. invisible.
- the platform (platform, 4.5 cm in diameter, 14.5 cm in height) was placed in the center of one of the quarters of the entire water tank so that the top of the platform was located 0.5 cm below the water surface.
- the device was installed in a laboratory with markings to identify the location. The training trial was conducted three times a day for five consecutive days. Once the mouse had found the platform, the next test was performed 5 minutes later, allowing the mouse to stay on the platform for about 10 seconds and return to the original cage.
- the mouse does not find a platform within 120 seconds, it is left on the platform for 10 seconds before testing.
- Probe test was performed 24 hours after the last training test in the trained animals. In this case, the platform was removed from the pool and the time spent in the quadrant where the platform was placed for 90 seconds was measured and expressed as a percentage.
- mice 16-month-old mice were given three Lactobacillus C29, C3, and C24 (1x10 9 CFU each) for 5 days a week for 12 weeks. Effects and aging related genes AKT, FOXO3, NF-kB (p65) and mTor phosphorylation were measured. Beta-actin was measured as a comparative gene. In addition, the memory improvement effect was measured.
- 100 ⁇ l of colon tissue of the test animal was homogenized by adding 250 ⁇ l of RIPA buffer containing a protease inhibitor cocktail. After centrifugation at 4 °C, 13000 rpm for 15 minutes, the supernatant was stored at -80 °C was used for lipid peroxidation analysis.
- Lipid peroxidation in colon tissue was analyzed using the TBARS assay kit (Cayman chem., USA). 100 ⁇ l of colon homogenate was placed in a 5 ml polypropylene screwcap centrifuge tube, then 100 ⁇ l of SDS solution was added and gently shaken. 4 ml of color reagent was added to the tube and then quenched in water for 1 hour to stop the reaction. Thereafter, the mixture was centrifuged at 4 DEG C and 13000 rpm for 10 minutes, and then allowed to stand at room temperature for 30 minutes, and the absorbance was measured at 540 nm using an ELISA reader. A standard curve was prepared using malonaldehyde (MDA) as a standard and the amount of MDA generated therefrom was measured.
- MDA malonaldehyde
- Zn-SOD activity was measured using xanthine oxidase-cytochrome C system.
- One unit of SOD was defined as the amount of SOD to inhibit a 50% reduction in cytochrome C.
- the GSH concentration was measured by diluting the sample with phosphate buffer, adding o-phthalaldehyde, shaking for 15 minutes, and measuring fluorescence at an excitation wavelength of 345 nm and an emission wavelength of 425 nm.
- 100 mg of colon tissue of the experimental animal was homogenized by adding 250 ⁇ l of RIPA buffer (Gibco) containing a protease inhibitor cocktail.
- RIPA buffer Gibco
- the supernatant was taken and subjected to electrophoresis for 1 h 30 min on SDS 10% (w / v) polyacrylamide gel (sample, 50 ⁇ g).
- the electrophoresis was transferred to nitrocellulose paper at 100 V and 400 mA for 1 hour 10 minutes, the transferred nitrocellulose paper was blocked with 5% skim milk for 30 minutes, washed with PBS-Tween 3 times for 5 minutes, and the primary antibody (Santa Cruz Biotechnology, USA) was reacted 1: 100 overnight. After washing three times for 10 minutes, the secondary antibody (Santa Cruz Biotechnology, USA) was reacted with 1: 1000 for 1 hour and 20 minutes. Thereafter, the mixture was washed three times for 15 minutes, and developed by fluorescence.
- the Y-shaped labyrinth measuring device extends three arms to form the letter Y, each branch 25 cm long, 14 cm high, 5 cm wide and positioned at the same angle. At the end of a passage in the Y-shaped labyrinth, the animal's head is pointed and free to wander about eight minutes. Record the movement of the animal and see it as an arm entry as it enters the passage to the animal's hind paw. The movement of an animal is expressed as alternation, which is defined as one crossing when the animal passes through three passages in a row. Voluntary crossover behavior is expressed as a percentage of the actual crossover and the maximum possible crossover (ie, the total crossover minus two).
- C29 lactic acid bacteria, C3 lactic acid bacteria and C24 lactic acid bacteria were administered 1 ⁇ 10 9 CFU (dogs) once a day for 2 days to 16-month-old mice.
- scopolamine was not administered because aging mice had less memory than young mice.
- a circular water tank (100 cm diameter, 35 cm high) was filled with powdered milk to a depth of 15 cm to make the platform installed in water at a temperature of 23 ° C. invisible.
- the platform (platform, 4.5 cm in diameter, 14.5 cm in height) was placed in the center of one of the quarters of the entire water tank so that the top of the platform was located 0.5 cm below the water surface.
- the device was installed in a laboratory with markings to identify the location. The training trial was conducted three times a day for five consecutive days. Once the mouse had found the platform, the next test was performed 5 minutes later, allowing the mouse to stay on the platform for about 10 seconds and return to the original cage.
- the mouse does not find a platform within 120 seconds, it is left on the platform for 10 seconds before testing.
- Probe test was performed 24 hours after the last training test in the trained animals. In this case, the platform was removed from the pool and the time spent in the quadrant where the platform was placed for 90 seconds was measured and expressed as a percentage.
- C29 lactic acid bacteria, C3 lactic acid bacteria, and C24 lactic acid bacteria were measured daily swimming time while administering 1 ⁇ 10 9 CFU (dog) once a day for 4 days each to 16-month-old mice.
- scopolamine was not administered because aging mice had less memory than young mice.
- the blast similarity survey program was used to compare the base sequences of rDNA, and to perform multiple sequence alignments with 16S rDNA gene sequences of various Lactobacillus spp. Strains. No. 999% homology with cerium strain BIM B-536 and Lactobacillus pentosus strain LS3 and named as Lactobacillus pentosus strain plantarium C29, dated July 9, 2012 to the Korea Microorganism Conservation Center (KCCM) Deposited with Accession No. KCCM11291P.
- KCCM Microorganism Conservation Center
- C3 lactobacillus was identified as Lactobacillus curbatus C3 with more than 99.9% homology with Lactobacillus curbatus, and was deposited with the deposit number KCCM43009 on July 9, 2012 to Korea Deposit Control Center (KCCM). .
- soybean or skim bean fermentation composition 0.1 ml of the soybean or skim bean fermentation composition, thaw skin fermentation composition, ginseng fermentation composition, and deodeok fermentation composition prepared by the above method were administered to mice, which were dementia animal models, once a day for 2 days.
- Scopolamine 0.9 mg / kg was administered 1 hour after the last dose of lactic acid bacteria.
- the soybean fermentation composition fermented with C29 is best maintained the memory for passive avoidance and is superior to tacrine (Tacrin, TAC, 10 mg / kg), a treatment for dementia
- ginseng fermentation composition fermented with C29, soybean fermentation composition fermented with C3, and deodeok fermentation composition fermented with C29 were followed. This shows that fermentation compositions fermented with C29 or C3 strains have a memory improving effect.
Abstract
Description
Claims (16)
- 락토바실러스 펜토서스 변종 플란타륨(Lactobacillus pentosus var. plantarum) C29 KCCM11291P.
- 락토바실러스 펜토서스 변종 플란타륨 C29 KCCM11291P 균주를 유효 성분으로 포함하는 항산화 및 항노화 약학 조성물.
- 락토바실러스 펜토서스 변종 플란타륨 C29 KCCM11291P 균주를 유효 성분으로 포함하는 치매의 예방 또는 치료용 약학 조성물.
- 락토바실러스 펜토서스 변종 플란타륨 C29 KCCM11291P 균주를 유효 성분으로 포함하는 항산화 및 항노화 효과를 가진 건강기능식품.
- 락토바실러스 펜토서스 변종 플란타륨 C29 KCCM11291P 균주를 유효 성분으로 포함하는 치매의 예방 또는 개선용 건강기능식품.
- 제3항에 있어서, 치매는 노인성 치매, 알츠하이머병, 혈관성 치매, 루이체 치매, 전측두엽 치매, 파킨슨병 치매, 헌팅턴병 치매, 정상압 뇌수두증에 의한 치매, 두부 외상으로 인한 치매, 및 물질로 유발된 치매로 이루어진 군으로부터 선택되는 약학 조성물.
- 제5항에 있어서, 치매는 노인성 치매, 알츠하이머병, 혈관성 치매, 루이체 치매, 전측두엽 치매, 파킨슨병 치매, 헌팅턴병 치매, 정상압 뇌수두증에 의한 치매, 두부 외상으로 인한 치매, 및 물질로 유발된 치매로 이루어진 군으로부터 선택되는 건강기능식품.
- 락토바실러스 쿠르바투스(Lactobacillus curvatus) C3 KCCM43009 균주를 유효 성분으로 포함하는 항산화 및 항노화 약학 조성물.
- 락토바실러스 쿠르바투스 C3 KCCM43009 균주를 유효 성분으로 포함하는 치매의 예방 또는 치료용 약학 조성물.
- 락토바실러스 쿠르바투스 C3 KCCM43009 균주를 유효 성분으로 포함하는 항산화 및 항노화 효과를 가진 건강기능식품.
- 락토바실러스 쿠르바투스 C3 KCCM43009 균주를 유효 성분으로 포함하는 치매의 예방 또는 개선용 건강기능식품.
- 제9항에 있어서, 치매는 노인성 치매, 알츠하이머병, 혈관성 치매, 루이체 치매, 전측두엽 치매, 파킨슨병 치매, 헌팅턴병 치매, 정상압 뇌수두증에 의한 치매, 두부 외상으로 인한 치매, 및 물질로 유발된 치매로 이루어진 군으로부터 선택되는 약학 조성물.
- 제11항에 있어서, 치매는 노인성 치매, 알츠하이머병, 혈관성 치매, 루이체 치매, 전측두엽 치매, 파킨슨병 치매, 헌팅턴병 치매, 정상압 뇌수두증에 의한 치매, 두부 외상으로 인한 치매, 및 물질로 유발된 치매로 이루어진 군으로부터 선택되는 건강기능식품.
- 락토바실러스 펜토서스 변종 플란타륨 C29 KCCM11291P 균주 또는 락토바실러스 쿠르바투스 C3 KCCM43009 균주로 발효된 발효 조성물을 유효 성분으로 포함하는 치매의 예방 또는 치료용 조성물.
- 제14항에 있어서, 상기 발효 조성물은 콩 또는 탈지콩 발효 조성물, 해동피 발효 조성물, 인삼 발효 조성물, 및 더덕 발효 조성물로 이루어진 군으로부터 선택되는 치매의 예방 또는 치료용 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015527374A JP6009080B2 (ja) | 2012-08-16 | 2013-08-16 | 老化及び認知症の予防及び/または治療活性を有する乳酸菌 |
US14/421,714 US20150306158A1 (en) | 2012-08-16 | 2013-08-16 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
CN201380044004.3A CN104781390B (zh) | 2012-08-16 | 2013-08-16 | 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌 |
HK16100354.2A HK1212387A1 (en) | 2012-08-16 | 2016-01-13 | Lactic acid bacteria capable of preventing and or treating senescence and dementia |
US15/297,955 US10874701B2 (en) | 2012-08-16 | 2016-10-19 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
US15/641,873 US10561691B2 (en) | 2012-08-16 | 2017-07-05 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0089714 | 2012-08-16 | ||
KR20120089714 | 2012-08-16 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/421,714 A-371-Of-International US20150306158A1 (en) | 2012-08-16 | 2013-08-16 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
US15/297,955 Division US10874701B2 (en) | 2012-08-16 | 2016-10-19 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
US15/641,873 Division US10561691B2 (en) | 2012-08-16 | 2017-07-05 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
US15/641,873 Continuation US10561691B2 (en) | 2012-08-16 | 2017-07-05 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014027864A1 true WO2014027864A1 (ko) | 2014-02-20 |
Family
ID=50268816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/007410 WO2014027864A1 (ko) | 2012-08-16 | 2013-08-16 | 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20150306158A1 (ko) |
JP (1) | JP6009080B2 (ko) |
KR (2) | KR101476236B1 (ko) |
CN (1) | CN104781390B (ko) |
HK (1) | HK1212387A1 (ko) |
WO (1) | WO2014027864A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016093104A1 (ja) * | 2014-12-09 | 2016-06-16 | 株式会社日本自然発酵 | 老化抑制剤 |
WO2016110768A1 (en) * | 2015-01-07 | 2016-07-14 | Ecole Polytechnique Federale De Lausanne (Epfl) | Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies |
CN112111430A (zh) * | 2020-09-27 | 2020-12-22 | 吉林农业大学 | 一种抗氧化与抗衰老双效益生菌及其应用 |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6009080B2 (ja) | 2012-08-16 | 2016-10-19 | ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティUniversity−Industry Cooperation Group Of Kyung Hee University | 老化及び認知症の予防及び/または治療活性を有する乳酸菌 |
US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
KR20170032815A (ko) * | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물 |
EP4268616A3 (en) * | 2016-05-31 | 2023-12-06 | Morinaga Milk Industry Co., Ltd. | Brain function improving agent |
JP6774664B2 (ja) | 2016-06-14 | 2020-10-28 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジーKorea Research Institute Of Bioscience And Biotechnology | 退行性脳疾患の予防又は治療効果を有するアガトバキュラム属菌株及びその用途 |
JP6898628B2 (ja) * | 2016-06-15 | 2021-07-07 | 国立大学法人広島大学 | 神経変性疾患治療剤 |
JP6757190B2 (ja) * | 2016-06-29 | 2020-09-16 | 株式会社ヤクルト本社 | 危機回避能力低下抑制剤 |
WO2018012834A1 (ko) | 2016-07-11 | 2018-01-18 | 한국생명공학연구원 | 퇴행성 뇌질환 또는 대사성 질환의 예방 또는 치료 효과를 가지는 아커만시아 뮤시니필라 균주 및 이의 용도 |
CN110325197A (zh) * | 2016-08-30 | 2019-10-11 | (株)库恩生物 | 用于防止脱发或促进毛发生长的包括展示脂肪分解作用的菌株的组合物 |
CN106399163B (zh) * | 2016-09-08 | 2019-09-27 | 江苏微康生物科技有限公司 | 一种抗衰老益生菌制剂及制备方法 |
CN106858606B (zh) * | 2016-12-28 | 2020-12-11 | 石家庄君乐宝乳业有限公司 | 具有抗氧化功能的益生菌粉及其制备方法 |
KR101801764B1 (ko) | 2017-06-01 | 2017-11-27 | 한국식품연구원 | 양모 촉진 활성을 갖는 락토바실러스 커베투스 wikim55 및 이를 포함하는 조성물 |
CN108048342B (zh) * | 2017-10-26 | 2021-06-04 | 中国农业大学 | 一种耐压益生菌及其食品和制备方法 |
KR101972236B1 (ko) | 2017-11-02 | 2019-04-24 | 서원대학교산학협력단 | 김치에서 분리한 락토바실러스 플란타룸 및 이의 용도 |
CN109182162B (zh) * | 2018-08-17 | 2021-10-26 | 哈尔滨美华生物技术股份有限公司 | 一株具有抗氧化能力的植物乳杆菌及应用 |
KR102162143B1 (ko) * | 2019-01-15 | 2020-10-07 | 한국식품연구원 | 페디오코쿠스 이노피나투스 wikim27을 포함하는 퇴행성 뇌질환의 예방, 개선 또는 치료용 조성물 |
CN110499263B (zh) * | 2019-07-12 | 2020-10-30 | 华东理工大学 | 一种植物乳杆菌x7022及其应用 |
JP6739602B1 (ja) * | 2019-07-24 | 2020-08-12 | 雪印メグミルク株式会社 | 記憶・学習能維持および/または向上用組成物及び組成物を含む食品、医薬品、飼料 |
JP6739603B1 (ja) * | 2019-07-24 | 2020-08-12 | 雪印メグミルク株式会社 | 記憶・学習能維持および/または向上用組成物及び組成物を含む食品、医薬品、飼料 |
KR20210055477A (ko) | 2019-11-07 | 2021-05-17 | 주식회사 에치와이 | 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물 |
KR102133721B1 (ko) * | 2019-12-12 | 2020-07-14 | 신연희 | 감 잎 발효물을 포함하는 항산화 효과를 갖는 기능성 식품 조성물 |
JP2021020885A (ja) * | 2020-03-09 | 2021-02-18 | 雪印メグミルク株式会社 | 記憶・学習能維持および/または向上用組成物及び組成物を含む食品、医薬品、飼料 |
IT202000007690A1 (it) * | 2020-04-09 | 2021-10-09 | Probiotical Spa | Uso di ceppi di batteri Lactobacillus plantarum e/o Lactobacillus pentosus nella riduzione di una quantità ingerita o accumulata di fosfonati nel microbiota umano |
KR102404659B1 (ko) | 2020-09-23 | 2022-06-07 | 주식회사 에치와이 | 락토바실러스 파라카제이 hp7 균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물 |
KR20220040017A (ko) * | 2020-09-23 | 2022-03-30 | 주식회사 프로바이오닉 | 락토바실러스 사케이 Probio-65를 포함하는 알츠하이머병의 예방 또는 치료용 조성물 |
KR102404657B1 (ko) | 2020-09-23 | 2022-06-07 | 주식회사 에치와이 | 락토바실러스 플란타룸 hy7715균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물 |
KR102404656B1 (ko) | 2020-09-23 | 2022-06-07 | 주식회사 에치와이 | 비피도박테리움 애니멀리스 서브스페시스 락티스 hy8002균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물 |
KR102404658B1 (ko) | 2020-09-23 | 2022-06-07 | 주식회사 에치와이 | 락토바실러스 카제이 hy2782 균주를 함유하는 인지기능장애 및 우울증 예방, 개선 또는 치료용 조성물 |
KR102396476B1 (ko) | 2020-10-29 | 2022-05-10 | 엠테라파마 주식회사 | 신규한 비피도박테리움 롱검 z1 균주 및 이의 용도 |
CN112386614B (zh) * | 2020-11-25 | 2022-11-08 | 天津科技大学 | 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用 |
KR102480131B1 (ko) * | 2020-12-14 | 2022-12-23 | 서울대학교산학협력단 | 인지능력 개선 기능을 가지는 락토바실러스 람노수스 |
KR102480136B1 (ko) * | 2020-12-14 | 2022-12-23 | 서울대학교산학협력단 | 인지능력 개선 기능을 가지는 락토바실러스 파라카제이 |
KR102480146B1 (ko) * | 2020-12-14 | 2022-12-23 | 서울대학교산학협력단 | 인지능력 개선 기능을 가지는 락토바실러스 아시도필루스 |
KR102572025B1 (ko) | 2021-02-02 | 2023-08-29 | 단국대학교 천안캠퍼스 산학협력단 | 신규한 류코노스톡 메젠테로이드 mkjw 균주 및 이의 용도 |
CN113521111B (zh) * | 2021-03-16 | 2024-02-06 | 浙江大学 | 青春双歧杆菌在衰老延缓方面的应用 |
KR20230085279A (ko) | 2021-12-06 | 2023-06-14 | 엠테라파마 주식회사 | 락토바실러스 파라카제이 nk112, 실새삼 추출물 및 새삼 추출물을 포함하는 인지기능 및 장기능 장애의 예방 또는 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070055372A (ko) * | 2005-11-24 | 2007-05-30 | 재단법인 제주하이테크산업진흥원 | 구아바 발효 조성물 및 그 용도 |
KR20070070153A (ko) * | 2004-06-23 | 2007-07-03 | 로레알 | 민감성 및/또는 건성 피부의 예방 및/또는 치료에 유용한방법 및 조성물 |
KR20110057550A (ko) * | 2009-11-24 | 2011-06-01 | 일동제약주식회사 | 치매, 치매관련 질환의 예방/치료 및 인지기능장애 개선에 효과가 있는 유산균 발효 산물, 이의 제조방법 및 용도 |
WO2011078781A1 (en) * | 2009-12-22 | 2011-06-30 | Probi Ab | Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7619005B2 (en) | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
KR20030088453A (ko) * | 2001-03-09 | 2003-11-19 | 소시에떼 데 프로듀이 네슬레 소시에떼아노님 | 연령 관련 생리학적 부전 개선 및 수명 연장을 위한 조성물 |
KR100503925B1 (ko) * | 2001-07-31 | 2005-07-27 | 김종덕 | 항산화성을 갖는, 장내 세균 성장촉진용 조성물 |
JP4119656B2 (ja) * | 2002-02-28 | 2008-07-16 | 雪印乳業株式会社 | 抗酸化剤 |
CN1511520A (zh) | 2002-12-31 | 2004-07-14 | �й�ҽѧ��ѧԺҩ���о��� | 丁二酸酯衍生物治疗痴呆症的用途 |
JP2007126399A (ja) * | 2005-11-04 | 2007-05-24 | Suntory Ltd | グルタチオン増加用組成物 |
US8440426B2 (en) * | 2007-04-18 | 2013-05-14 | Kigen Biogenics Institute Co., Ltd. | Method for production of antimutagenic substance using lactic acid bacterium |
US20110027348A1 (en) * | 2007-08-27 | 2011-02-03 | Janos Feher | Composition and method inhibiting inflammation |
KR101010914B1 (ko) * | 2008-04-28 | 2011-01-26 | 주식회사 엔유씨전자 | 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄 |
HUE038141T2 (hu) | 2009-04-13 | 2018-10-29 | Theravance Biopharma R&D Ip Llc | 5-HT4 receptor agonisták és acetilkolinészteráz inhibitorok kombinációi kognitív rendellenességek kezelésére |
JP5667358B2 (ja) | 2009-06-03 | 2015-02-12 | 富士産業株式会社 | 柑橘類果皮の麹菌発酵組成物 |
JP5155961B2 (ja) * | 2009-07-17 | 2013-03-06 | 雪印メグミルク株式会社 | 加齢に伴う代謝異常症の予防・改善・治療剤 |
US8257761B2 (en) * | 2009-12-15 | 2012-09-04 | Jacob Ludwig Manfred | Polyphenol-containing products |
JP6009080B2 (ja) | 2012-08-16 | 2016-10-19 | ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティUniversity−Industry Cooperation Group Of Kyung Hee University | 老化及び認知症の予防及び/または治療活性を有する乳酸菌 |
US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
-
2013
- 2013-08-16 JP JP2015527374A patent/JP6009080B2/ja active Active
- 2013-08-16 CN CN201380044004.3A patent/CN104781390B/zh active Active
- 2013-08-16 KR KR1020130097445A patent/KR101476236B1/ko active IP Right Grant
- 2013-08-16 US US14/421,714 patent/US20150306158A1/en not_active Abandoned
- 2013-08-16 WO PCT/KR2013/007410 patent/WO2014027864A1/ko active Application Filing
-
2014
- 2014-10-17 KR KR20140140809A patent/KR20140131894A/ko not_active Application Discontinuation
-
2016
- 2016-01-13 HK HK16100354.2A patent/HK1212387A1/xx unknown
-
2017
- 2017-07-05 US US15/641,873 patent/US10561691B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070070153A (ko) * | 2004-06-23 | 2007-07-03 | 로레알 | 민감성 및/또는 건성 피부의 예방 및/또는 치료에 유용한방법 및 조성물 |
KR20070055372A (ko) * | 2005-11-24 | 2007-05-30 | 재단법인 제주하이테크산업진흥원 | 구아바 발효 조성물 및 그 용도 |
KR20110057550A (ko) * | 2009-11-24 | 2011-06-01 | 일동제약주식회사 | 치매, 치매관련 질환의 예방/치료 및 인지기능장애 개선에 효과가 있는 유산균 발효 산물, 이의 제조방법 및 용도 |
WO2011078781A1 (en) * | 2009-12-22 | 2011-06-30 | Probi Ab | Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016093104A1 (ja) * | 2014-12-09 | 2016-06-16 | 株式会社日本自然発酵 | 老化抑制剤 |
JP6013670B1 (ja) * | 2014-12-09 | 2016-10-25 | 株式会社日本自然発酵 | 老化抑制剤 |
CN106999521A (zh) * | 2014-12-09 | 2017-08-01 | 株式会社日本自然发酵 | 老化抑制剂 |
US10226441B2 (en) | 2014-12-09 | 2019-03-12 | Nihon Sizen Hakkoh Co., Ltd. | Aging inhibitor |
WO2016110768A1 (en) * | 2015-01-07 | 2016-07-14 | Ecole Polytechnique Federale De Lausanne (Epfl) | Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies |
CN112111430A (zh) * | 2020-09-27 | 2020-12-22 | 吉林农业大学 | 一种抗氧化与抗衰老双效益生菌及其应用 |
CN112111430B (zh) * | 2020-09-27 | 2022-10-21 | 吉林农业大学 | 一种抗氧化与抗衰老双效益生菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20170368114A1 (en) | 2017-12-28 |
CN104781390B (zh) | 2017-07-28 |
US20150306158A1 (en) | 2015-10-29 |
US10561691B2 (en) | 2020-02-18 |
HK1212387A1 (en) | 2016-06-10 |
KR101476236B1 (ko) | 2014-12-24 |
JP2015526085A (ja) | 2015-09-10 |
CN104781390A (zh) | 2015-07-15 |
KR20140023241A (ko) | 2014-02-26 |
KR20140131894A (ko) | 2014-11-14 |
JP6009080B2 (ja) | 2016-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014027864A1 (ko) | 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균 | |
WO2019151843A1 (ko) | 락토바실러스 플란타럼 kbl396 균주 및 그 용도 | |
WO2019216662A1 (ko) | 락토바실러스 파라카제이 균주 및 그 용도 | |
WO2015122717A1 (ko) | 비만 억제 효능을 갖는 신규 유산균 및 이의 용도 | |
US10874701B2 (en) | Lactic acid bacteria capable of preventing and/or treating senescence and dementia | |
WO2011010770A1 (ko) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 | |
WO2017074037A1 (ko) | 효소 생산능이 우수한 전통 발효식품 유래 신규 균주 및 이를 이용하여 곡물 발효 효소식품을 제조하는 방법 | |
WO2019226002A1 (ko) | 락토바실러스 크리스파투스 kbl693 균주 및 그 용도 | |
WO2019098810A2 (ko) | 신규 유산균 및 이의 용도 | |
WO2018164468A1 (en) | Bacillus amyloliquefaciens gf423 strain, and composition for providing antioxidant and anti-inflammatory activities or preventing or treating hyperlipidemia, including polypeptide produced by the same | |
WO2021060945A1 (ko) | 암 치료를 위한 절대혐기성 인체 장내미생물 및 이의 용도 | |
WO2019088379A1 (ko) | 신규 유산균 및 이의 용도 | |
WO2017131402A1 (ko) | 면역조절 작용을 가는 사람 소화관 유래 신규 유산균 및 이의 용도 | |
WO2023055188A1 (ko) | 신규 프로바이오틱스 및 이의 용도 | |
WO2017047962A1 (ko) | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능 장애의 예방, 개선 또는 치료용 조성물 | |
WO2018043874A1 (ko) | 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2011031083A2 (ko) | 칠황버섯 균사체를 이용한 발효식품 및 그 제조방법 | |
WO2016093450A1 (ko) | 신규한 균주로 알러지, 아토피성 피부염, 비염, 가려움증 등의 개선치료 및 면역력조절 기능을 갖는 락토바실러스 플랜타럼 k-1 br 균주 | |
WO2020180037A1 (ko) | 인간 장내 미생물 군집 모사 배양용 조성물, 혐기 배양 체계를 이용한 인간 장내 미생물 군집의 모사 배양 방법, 이에 의해 제조된 미생물 제제 및 이의 용도 | |
WO2018034492A1 (ko) | 페디오코쿠스 펜토사세우스를 유효성분으로 포함하는 th1-매개 면역 질환, th17-매개 면역 질환 또는 th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물 | |
WO2020045972A1 (ko) | 항비만 활성을 갖는 인체 유래 락토바실러스 퍼멘툼 엠지4231 또는 락토바실러스 퍼멘툼 엠지4244 균주 및 이를 포함하는 조성물 | |
WO2022039561A1 (ko) | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 | |
WO2022163971A1 (ko) | 콜린에스터라제 억제제 및 항산화제를 포함하는 뇌질환 치료용 약학적 복합 조성물 | |
WO2021020923A1 (ko) | 간 손상 예방, 개선, 또는 치료용 조성물 및 간 손상 예방, 개선, 또는 치료방법 | |
WO2011055927A2 (ko) | 초산성 생장 혼합 미생물 조성물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13879420 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14421714 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015527374 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13879420 Country of ref document: EP Kind code of ref document: A1 |